Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go

Frontiers in Immunology
Angela VasaturoStanleyson V Hato

Abstract

The aim of therapeutic dendritic cell (DC) vaccines in cancer immunotherapy is to activate cytotoxic T cells to recognize and attack the tumor. T cell activation requires the interaction of the T cell receptor with a cognate major-histocompatibility complex-peptide complex. Although initiated by antigen engagement, it is the complex balance between co-stimulatory and co-inhibitory signals on DCs that results in T cell activation or tolerance. Even when already activated, tumor-specific T cells can be neutralized by the expression of co-inhibitory molecules on tumor cells. These and other immunosuppressive cues in the tumor microenvironment are major factors currently hampering the application of DC vaccination. In this review, we discuss recent data regarding the essential and complex role of co-inhibitory molecules in regulating the immune response within the tumor microenvironment. In particular, possible therapeutic intervention strategies aimed at reversing or neutralizing suppressive networks within the tumor microenvironment will be emphasized. Importantly, blocking co-inhibitory molecule signaling, often referred to as immune checkpoint blockade, does not necessarily lead to an effective activation of tumor-specific T ce...Continue Reading

Citations

Aug 10, 2015·Biochimica Et Biophysica Acta·Emyr BakkerMarija Krstic-Demonacos
Mar 3, 2015·Gynecologic Oncology·Christina WefersStanleyson V Hato
Mar 19, 2015·Frontiers in Immunology·Gabriela Andrea Pizzurro, María Marcela Barrio
May 24, 2016·Mediators of Inflammation·Ceren EyiletenTomasz P Rygiel
May 17, 2014·Frontiers in Immunology·Harm WestdorpI Jolanda M de Vries
May 6, 2014·Frontiers in Immunology·Kristian Michael Hargadon, Timothy N J Bullock
Aug 5, 2015·Pharmacological Reviews·Sébastien AnguilleZwi N Berneman
Apr 15, 2016·Journal of Translational Medicine·Jurjen TelStanleyson V Hato
Feb 28, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Dirk Theile
Sep 8, 2018·Frontiers in Oncology·Henry T Marshall, Mustafa B A Djamgoz
Mar 31, 2018·Frontiers in Immunology·Maarten VerstevenEva Lion
Feb 21, 2018·Frontiers in Oncology·Sanghamitra MylavarapuMonideepa Roy
Mar 15, 2018·Frontiers in Immunology·Felix S LichteneggerMarion Subklewe
Oct 18, 2018·Frontiers in Immunology·Wouter W van WilligenKalijn F Bol
Jan 18, 2019·FEBS Open Bio·Marisol de la Fuente-GranadaGloria Soldevila
Dec 21, 2018·Frontiers in Immunology·Mandy van GulijkHeleen Vroman
Jun 19, 2019·Journal of Cellular and Molecular Medicine·Jingyi ZhouZhengdong Cai
Dec 19, 2018·Frontiers in Immunology·Kristen B LongJoseph A Fraietta
Jun 1, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stanleyson V HatoW Joost Lesterhuis
Jan 12, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Luciano CastielloDavid F Stroncek
Apr 28, 2021·Bulletin du cancer·Thomas TingryCyrille B Confavreux
Aug 20, 2020·Journal of Medicinal Chemistry·Chunqiu YuJing-Jing Zhang
Oct 13, 2021·Chemical Society Reviews·Shukun TangQun Wang

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT00658892
NCT01721772

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

Human Vaccines & Immunotherapeutics
Mieke W H RoevenHarry Dolstra
Methods : a Companion to Methods in Enzymology
Joseph G Altin, Christopher R Parish
Annual Review of Medicine
J M Timmerman, R Levy
© 2021 Meta ULC. All rights reserved